Can Substance-Induced Psychoses (SIP) Shed Light on the Paradigm of Schizophrenia?
Alessio Mosca, Filippo Maria Ferro
2026, 2(1): 5. doi: 10.53941/cna.2026.100005
Aripiprazole Long Acting and Clozapine: Between Efficacy and Tolerability
Luca Persico, Ludovica Di Sante, Michele Xynelis, Andrea Miuli, Alessio Mosca, Mauro Pettorruso
2026, 2(1): 4. doi: 10.53941/cna.2026.100004
Brexpiprazole in the Management of Schizophrenia and Comorbid Substance Use Disorders: A Narrative Review of Efficacy, Safety, and Real-World Evidence (2020–2026)
Miriam Olivola, Nicolaja Girone, Andrea Crippa, Monica Macellaro, Vassilis Martiadis, Fabiola Raffone, Tiziano Prodi, Natascia Brondino, Roberta Anniverno, Bernardo Dell’Osso
2026, 2(1): 3. doi: 10.53941/cna.2026.100003

Improved Migraine Disability, Sleep Quality, and Well-Being in Individuals with Chronic Migraine Self-Administering Artisanal or Industrial Full-Spectrum Cannabidiol-Rich Oils: An Observational Cohort Study
Linério Ribeiro de Novais Júnior, Larissa Mendes da Silva, Vicente Meneguzzo, Suelen de Souza Ramos, Lara Rodrigues da Rosa, Tiago Odilio de Souza, João Victor Simão, Alisson Reuel da Silva, Josiel Mack, Kelser de Souza Kock, Mariana Pereira de Souza Goldim, Antonio Inserra, Rafael Mariano de Bitencourt
2026, 2(1): 2. doi: 10.53941/cna.2026.100002
Ketamine-Related Deaths Registered in Scotland 2013–2024
John Martin Corkery, Amira Guirguis, Fabrizio Schifano
2026, 2(1): 1. doi: 10.53941/cna.2026.100001